Disseminated gene delivery to the CNS by human iPSC-derived neural stem cells
通过人类 iPSC 衍生的神经干细胞将播散性基因传递至 CNS
基本信息
- 批准号:9204865
- 负责人:
- 金额:$ 36.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-02-01 至 2020-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultAffectAffinityAnimal ModelBiologyBrainBrain DiseasesCell Culture TechniquesCell TherapyCell TransplantationCell TransplantsCellsCentral Nervous System DiseasesChildhoodClinicalDataDefectDevelopmentDiffuseDiseaseElectrophysiology (science)EngineeringEngraftmentEnvironmentEnzymesFibroblastsFutureGene DeliveryGene TransferGoalsGrantHereditary DiseaseHumanHuman EngineeringHuman GeneticsIn VitroIndividualInheritedInjection of therapeutic agentLesionLifeLysosomal Storage DiseasesMeasuresMediatingMeta-AnalysisMethodsMucopolysaccharidosis VIIMusNOD/SCID mouseNatureNeuronsNotch Signaling PathwayOutcomePathologyPathway interactionsPatientsPatternPluripotent Stem CellsPropertyProteinsResearchSafetySiteSomatic CellStem cellsStructureTestingTherapeuticTimeTissuesTranslatingTranslationsTransplantationTreatment EfficacyUp-RegulationXenograft procedurebasecell motilitycell typecellular engineeringclinical developmentcommon treatmentdensitydysmyelinationeffective therapyexperimental studygray matterhuman diseaseimprovedin vivoinduced pluripotent stem cellmethod developmentmigrationmouse modelmutantnerve stem cellneurogeneticsneuropathologypublic health relevancerepairedstem cell therapysubventricular zonetherapeutic effectivenesstherapeutic evaluationtranscription factortranscriptometranslational studytreatment strategywhite matter
项目摘要
DESCRIPTION (provided by applicant): The natural ability of neural stem cells (NSCs) to migrate within the brain, under certain circumstances, has long made them a candidate for treatment of CNS diseases. The development of methods to reprogram human somatic cells into tissue specific stem cells has provided great hope for using NSC therapies for many brain disorders. NSC transplantation experiments in mouse models of human diseases have demonstrated correction of at least some pathology in several types of diseases, providing proof-of-principle for the NSC- based approach. However, a significant barrier to effective translation is the low level of engraftment that occurs. Neurogenetic diseases have globally distributed lesions in the CNS due to the nature of the defect, thus treatment requires disseminated distribution of the donor cells. Achieving that will, however, require much better understanding of the post-transplantation properties of NSCs. We have reprogrammed human patient fibroblasts into pluripotent stem cells (iPSCs), derived NSCs from them, and genetically corrected the hu-iPS- NSCs. We propose xenograft studies to evaluate the effects of engineering hu-iPS-NSCs on post-transplant distribution and survival. We will test the therapeutic effectiveness of delivering a diffusible protein within the brain, in a well-characterized mouse model of a human lysosomal storage disease (LSD). There are >50 individual LSDs and they are responsible for a large portion of all inherited childhood genetic diseases that affect the CNS. A common treatment strategy can be used, in principle, for most of the LSD's, based on the observation that lysosomal enzymes are exported from genetically corrected cells and taken up by mutant cells to restore the missing enzymatic activity. Preliminary studies indicate the hu-iPS-NSCs engraft in the NOD- SCID mouse brain at low levels. The proposed experiments will investigate basic features of post-transplant dispersion and survival of the donor cells to address the problem of inadequate NSC engraftment. We have obtained compelling preliminary data demonstrating the feasibility of the proposed experiments and we will use quantitative analyses to measure amounts of engraftment, differentiation into mature neural cell types, and changes in pathology. The long-term strategy of this line of research is to develop NSC transplants in the mouse brain to a level where they can be tested in large animal models of brain diseases in future translational studies and eventually into the human brain which is ~3,000 times larger than the mouse brain. It is clear that progress on this problem needs significant advances in understanding the biology of NSC engraftment and development of strategies to enhance engraftment.
描述(由申请人提供):神经干细胞(NSC)在某些情况下在脑内迁移的天然能力长期以来使其成为治疗CNS疾病的候选者。将人类体细胞重编程为组织特异性干细胞的方法的发展为使用NSC治疗许多脑疾病提供了巨大的希望。在人类疾病的小鼠模型中的NSC移植实验已经证明了在几种类型的疾病中至少一些病理学的校正,为基于NSC的方法提供了原理证明。然而,有效翻译的一个重要障碍是移植水平低。由于缺陷的性质,神经遗传性疾病在CNS中具有全局分布的病变,因此治疗需要供体细胞的弥散分布。然而,要实现这一目标,需要更好地了解神经干细胞移植后的特性。我们已经将人类患者成纤维细胞重编程为多能干细胞(iPSC),从它们衍生NSC,并遗传校正hu-iPS-NSC。我们提出异种移植研究来评估工程化hu-iPS-NSC对移植后分布和存活的影响。我们将测试在脑内递送可扩散蛋白质的治疗效果,在人溶酶体贮积病(LSD)的良好表征的小鼠模型中。有超过50种LSD,它们是影响CNS的所有遗传性儿童遗传疾病的大部分原因。原则上,基于溶酶体酶从遗传校正的细胞输出并被突变细胞吸收以恢复缺失的酶活性的观察,可以对大多数LSD使用常见的治疗策略。初步研究表明,hu-iPS-NSC以低水平植入NOD-SCID小鼠脑中。拟议的实验将调查移植后分散和供体细胞的存活的基本特征,以解决NSC植入不足的问题。我们已经获得了令人信服的初步数据,证明了拟议实验的可行性,我们将使用定量分析来测量植入量,分化为成熟神经细胞类型和病理变化。这项研究的长期战略是在小鼠大脑中开发NSC移植物,使其能够在未来的转化研究中在大脑疾病的大型动物模型中进行测试,并最终进入比小鼠大脑大3,000倍的人脑。很明显,在这个问题上的进展需要在理解NSC植入的生物学和发展策略以提高植入方面取得重大进展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN H WOLFE其他文献
JOHN H WOLFE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN H WOLFE', 18)}}的其他基金
Translational studies on cerebrospinal fluid (CSF)-directed gene therapy for global neurometabolic brain disease
脑脊液(CSF)定向基因治疗全球神经代谢性脑疾病的转化研究
- 批准号:
10379947 - 财政年份:2019
- 资助金额:
$ 36.75万 - 项目类别:
Translational studies on cerebrospinal fluid (CSF)-directed gene therapy for global neurometabolic brain disease
脑脊液(CSF)定向基因治疗全球神经代谢性脑疾病的转化研究
- 批准号:
9893931 - 财政年份:2019
- 资助金额:
$ 36.75万 - 项目类别:
Translational studies on cerebrospinal fluid (CSF)-directed gene therapy for global neurometabolic brain disease
脑脊液(CSF)定向基因治疗全球神经代谢性脑疾病的转化研究
- 批准号:
9763064 - 财政年份:2019
- 资助金额:
$ 36.75万 - 项目类别:
Translational studies on cerebrospinal fluid (CSF)-directed gene therapy for global neurometabolic brain disease
脑脊液(CSF)定向基因治疗全球神经代谢性脑疾病的转化研究
- 批准号:
10599930 - 财政年份:2019
- 资助金额:
$ 36.75万 - 项目类别:
Disseminated gene delivery to the CNS by human iPSC-derived neural stem cells
通过人类 iPSC 衍生的神经干细胞将播散性基因传递至 CNS
- 批准号:
8894955 - 财政年份:2015
- 资助金额:
$ 36.75万 - 项目类别:
Disseminated gene delivery to the CNS by human iPSC-derived neural stem cells
通过人类 iPSC 衍生的神经干细胞将播散性基因传递至 CNS
- 批准号:
8997131 - 财政年份:2015
- 资助金额:
$ 36.75万 - 项目类别:
Gene Transfer and NMR Studies in Alpha-Mannosidosis Brain
α-甘露糖苷沉积症脑中的基因转移和核磁共振研究
- 批准号:
8068082 - 财政年份:2010
- 资助金额:
$ 36.75万 - 项目类别:
Stem Cell Transplantation for Neurogenetic Disease
干细胞移植治疗神经遗传性疾病
- 批准号:
8094219 - 财政年份:2007
- 资助金额:
$ 36.75万 - 项目类别:
Stem Cell Transplantation for Neurogenetic Disease
干细胞移植治疗神经遗传性疾病
- 批准号:
7459697 - 财政年份:2007
- 资助金额:
$ 36.75万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 36.75万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 36.75万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 36.75万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 36.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 36.75万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 36.75万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 36.75万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 36.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 36.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 36.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)